Patent Assignment
Reel/Frame 042742/0922
Security Interest
Recorded: 2017-06-08
Received: 2017-06-08
Pages: 31
Assignor
ENDO PHARMACEUTICALS INC
Executed: 2017-04-27
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
1100 NORTH MARKET STREET, WILMINGTON, DE, 19890, UNITED STATES
Covered Properties
(28)
Sustained Release Formulation of Nalbuphine
Application:
15/162,062 →
Oxymorphone Controlled Release Compositions
Application:
14/798,619 →
Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride
Application:
14/613,421 →
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
Application:
14/336,753 →
Sustained Release Formulation of Nalbuphine
Application:
14/319,833 →
Sustained Release Formulation of Nalbuphine
Application:
14/290,413 →
Sustained Release Matrix Systems for Highly Soluble Drugs
Application:
14/195,127 →
Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride
Application:
14/091,399 →
Sustained Release Formulation of Nalbuphine
Application:
13/773,136 →
Chronotherapeutic Dosage Forms and Methods of Treatment Using Chronotherapy
Application:
12/985,137 →
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
Application:
12/716,973 →
Chronotherapeutic dosage forms
Application:
12/380,642 →
Sustained Release Formulations of Nalbuphine
Application:
12/154,496 →
Method for Making Analgesics
Application:
11/866,840 →
Sustained Release Matrix Systems for Highly Soluble Drugs
Application:
11/729,024 →
Oxymorphone Controlled Release Formulations
Application:
11/680,432 →
Treatment of Xerostomia
Application:
11/605,983 →
Sustained release formulations of nalbuphine
Application:
11/509,347 →
Oxymorphone Controlled Release Formulations
Application:
11/427,438 →
Particulate Drug-Containing Products and Method of Manufacture
Application:
10/717,429 →
High-Concentration Protein Formulations and Method of Manufacture
Application:
10/271,832 →
Intradermal-Penetration Agents for Topical Local Anesthetic Administration
Application:
10/201,901 →
Sustained Release Formulations of Oxymorphone
Application:
10/189,932 →
Oxymorphone controlled release formulations
Application:
10/190,192 →
Treatment of Mucositis
Application:
09/993,383 →
Composition for Delivery of Hematopoietic Growth Factor
Application:
09/893,339 →
Methods for Use of Delivery Composition for Expanding, Activating, Committing or Mobilizing One or More Pluripotent, Self-Renewing and Committed Stem Cells
Application:
09/893,372 →
Delivery Vehicle Composition and Methods for Delivering Antigens and Other Drugs
Application:
09/888,235 →